AMG National Trust Bank Boosts Stake in Stryker Corporation $SYK

AMG National Trust Bank boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 18.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 18,422 shares of the medical technology company’s stock after buying an additional 2,927 shares during the quarter. AMG National Trust Bank’s holdings in Stryker were worth $6,053,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of SYK. VanderPol Investments L.L.C. lifted its holdings in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC increased its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares during the last quarter. Rossby Financial LCC raised its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares in the last quarter. Tcfg Wealth Management LLC raised its holdings in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp boosted its position in shares of Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.7%

Shares of NYSE SYK opened at $332.20 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market cap of $127.35 billion, a P/E ratio of 38.45, a PEG ratio of 2.11 and a beta of 0.77. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The firm has a 50-day simple moving average of $310.47 and a two-hundred day simple moving average of $337.68.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the company posted $2.84 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock worth $100,659,489 in the last 90 days. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on SYK. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Leerink Partners dropped their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Truist Financial restated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.